Background
Methods
Study cohort
DNA methylation analyses
Expression analyses in normal breast tissue, tumors and cancer cell lines
DNA alkylation damage detection
Tissue microarrays (TMAs)
Informatics and statistical analyses
Results
Methylome analyses identify ALKBH3 as a target of CpG promoter methylation in breast cancer
Epigenetics and expression of ALKBH3 in normal breast epithelial cells
ALKBH3 epigenetic repression found in two breast cancer cell lines
CpG promoter methylation and expression of the ALKBH3 gene in normal and primary breast tumor samples
ALKBH3 promoter methylation with respect to clinical relevance
Positive
|
Negative
| |||
---|---|---|---|---|
Estrogen-Receptor | 175 (72%) | 68 (28%) | ||
Progestrone-Receptor | 136 (56%) | 108 (44%) | ||
HER2-positive (over-expressed) | 20 (14%) | 121 (86%) | ||
Ki67-positive (>14% positivity) | 84 (60%) | 55 (40%) | ||
1986–1991
|
1991–1996
|
1996–2001
|
2001–2004
| |
Year of Diagnosis | 81 (30%) | 121 (46%) | 60 (23%) | 3 (1%) |
26–42
|
42–58
|
58–74
|
74–91
| |
Age at Diagnosis | 36 (14%) | 104 (39%) | 80 (30%) | 45 (17%) |
5–30
|
30–55
|
55–80
|
80–100
| |
Tumour size (mm) | 94 (77%) | 24 (20%) | 1 (1%) | 3 (2%) |
Nodal status | 112 (64%) | 63 (36%) | ||
+
|
++
|
+++
| ||
Histological Grade | 19 (13%) | 62 (41%) | 69 (46%) |